Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)
- 1 March 2006
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (3) , 432-444
- https://doi.org/10.1016/j.clinthera.2006.03.012
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE StudyAnnals of Internal Medicine, 2003
- Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), NorwayAmerican Journal of Kidney Diseases, 2003
- Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?Nephrology Dialysis Transplantation, 2003
- Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General PopulationCirculation, 2002
- A cardiovascular life historyPublished by Oxford University Press (OUP) ,2002
- Global Burden of Cardiovascular DiseasesCirculation, 2001
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic IndividualsJAMA, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Urinary Albumin ExcretionArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Cardiovascular disease in the Netherlands, 1975 to 1995: decline in mortality, but increasing numbers of patients with chronic conditionsHeart, 1999